August 20, 2020Open Access
Evinacumab for Homozygous Familial Hypercholesterolemia
Key Result
Evinacumab reduced LDL cholesterol levels by 49.0 percentage points compared to a small increase in the placebo group at 24 weeks in patients with homozygous familial hypercholesterolemia.
Structured PICO
Does evinacumab reduce LDL cholesterol levels in patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy?
P
Population
Patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy
I
Intervention
Evinacumab
C
Comparator
Placebo
O
Outcome
Reduction from baseline in the LDL cholesterol level at 24 weekssurrogate
Evinacumab significantly reduces LDL cholesterol levels in patients with homozygous familial hypercholesterolemia already on maximum lipid-lowering therapy.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
F
Frederick J. Raal
Preventive Cardiology
Robert S. Rosenson
Preventive Cardiology
L
Laurens F. Reeskamp
Broad Institute
Journals
New England Journal of Medicine
Actions
Institutions
University of Amsterdam
Icahn School of Medicine at Mount Sinai
University of the Witwatersrand
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...